Fabiana Pancani
Florence, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia.
Journal: American journal of hematology
Published: March 16, 2026
Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency.
Journal: Haematologica
Published: November 18, 2025
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML.
Journal: Blood cancer journal
Published: December 17, 2024
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting.
Journal: Haematologica
Published: June 10, 2024
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
Journal: American journal of hematology
Published: September 14, 2023
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia.
Journal: Haematologica
Published: March 24, 2023
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates.
Journal: American journal of hematology
Published: June 20, 2022
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.
Journal: Blood cancer journal
Published: March 30, 2022
Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience.
Journal: Journal of clinical medicine
Published: February 23, 2021
Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category.
Journal: Cancers
Published: September 30, 2020
Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia.
Journal: American journal of hematology
Published: July 14, 2020
Last Updated: 09/26/2026